ClinicalTrials.gg
RecruitingNCT03190928Updated Nov 17, 2026

Clonal Evolution in Follicular Lymphoma

An observational study in Follicular Lymphoma, sponsored by National Cancer Institute (NCI). Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by National Cancer Institute (NCI) · Observational

How we know

From the registry’s dates

  • Started Jul 2017; still recruiting 9 years 3 months later.
Updated Nov 4, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 111 studies in Lymphoma, Follicular by National Cancer Institute (NCI) — 3 open to participants now, 12 under way, 1 of them phase 3. Lymphoma, Follicular · National Cancer Institute (NCI).

Started
2017
the only one that year
Observational
2 of 111
1 open now
Primary completion
2029-01
later than 10 of 11 live
Registered
103rd of 111
by date

Among the 111 studies in Lymphoma, Follicular by National Cancer Institute (NCI), this one is the only one that started in 2017, is one of 2 observational ones, reaches primary completion later than 10 of the 11 other live ones, and was the 103rd registered.

Lymphoma, Follicular

1,893 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

3 of the 111 studies in Lymphoma, Follicular by National Cancer Institute (NCI) are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 226 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies in Lymphoma, Follicular by National Cancer Institute (NCI), or all of them as a file.
02

Study summary

Background:

Follicular lymphoma is a type of cancer of the lymph nodes. Lab studies are important for cancer research. They help scientists better understand differences in the cancer biology of different patients. Researchers want to collect serial samples over time from people with follicular lymphoma to help them design future treatments.

Objective:

To collect a variety of samples from people with follicular lymphoma to study how these diseases progress and respond to treatment.

Eligibility:

Adults at least 18 years old who have been diagnosed with, but have not yet had any treatment for, follicular lymphoma.

Design:

Participants will be screened with medical history and physical exam. They will answer questions about daily functioning. They will have blood and urine tests. They may have scans and have tissue samples taken.

Participants will be monitored about every 4 months for up to 2 years. They will repeat screening tests. They will have a cheek swab. A small brush will be rubbed against the inside of the cheek to wipe off some cells.

Participants will have imaging scans about every 8 months for up to 2 years.

Participants may have a bone marrow aspiration and biopsy. The hipbone will be numbed with a small needle.

A needle will be put into the hipbone, and about 2 tablespoons of bone marrow will be taken out through the needle.

Participants will continue being monitored every 6 months for up to 5 years, then 1 time a year.

Read the detailed description

Background:

  • Follicular lymphoma (FL) is the second most common form of non-Hodgkin lymphoma and is incurable with standard first-line systemic therapy
  • The clinical course of FL varies from slowly progressive over many years to a more rapid disease course that requires therapy shortly after diagnosis
  • Early initiation of therapy does not improve survival, and asymptomatic individuals are often managed with an initial period of watchful waiting
  • Clinical prognostic indices predict survival, but cannot predict outcome for individual patients; biologic-based classifiers (gene-expression profiling and somatic mutational analyses) are more robust than clinical indices, but require prospective clinical validation from the time of diagnosis in the modern treatment era
  • Paired samples linked to clinical information can lead to the discovery and/or validation of therapeutic targets for FL patients at the highest risk of early disease progression

Objective:

Characterize the molecular biology and clinical course of FL patients, and evaluate the time to treatment initiation for those participants who require first-line systemic therapy

Eligibility:

  • Follicular lymphoma (grade 1-2, 3a) with no evidence of histological transformation
  • No previous cytotoxic, biologic or monoclonal antibody therapy for FL (previous radiation therapy permitted)
  • Age greater than or equal to 18 years
  • ECOG performance status of 0-2

Design:

  • Individuals with FL who meet all eligibility criteria will enroll on the study for expert monitoring of their disease, improved risk-stratification, and donation of tissue and cellular products for research. Participants will be monitored prospectively until they require second-line systemic treatment or the participant decides to withdraw from the study; untreated participants will be followed with clinic visits every 4 months for the first 2 years. After 2 years, protocol-specified visits will be increased to every 6 months until 5 years. After 5 years, protocol-specified visits will be annually until disease progression requiring first-line therapy.
  • Participants without an indication for first-line systemic therapy at 2 years from initial study enrollment will be offered an optional biopsy of their lymph node and bone marrow.
  • During first-line systemic therapy, participants can continue being monitored on this study for post-therapy clonal evolution. Protocol-specified visits after therapy will be every 6 months until 3 years. After 3 years, protocol-specified visits will be annually until disease progression requiring second-line therapy.
  • Upon initiation of second-line therapy, if applicable, participants will move to survival follow-up only.
03

Conditions studied

  • Follicular Lymphoma

Keywords

  • Disease Monitoring
  • Molecular Monitoring
  • Novel Biomarker Identification
  • Gene Expression Analyses
  • Watchful-Waiting
  • Natural History
04

Who can participate

The criteria were revised on the registry on Nov 4, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Up to 200 participants with pathologically-confirmed follicular lymphoma (grades 1-2, 3a) will be enrolled and screened for eligibility, and up to 75 eligible participants will receive active surveillance on this study for the purpose of expert monitoring of their disease, improved risk-stratification, and donation of tissue and cellular products for research.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed follicular lymphoma (FL), grades 1-2, or 3a confirmed by the Laboratory of Pathology, NCI; individuals who meet criteria for immediate initiation of systemic therapy are eligible
  • Adequate tissue available from original diagnostic .

NOTE: If biopsy was >12 months prior to enrollment OR adequate tissue is not available, tissue biopsy may be optionally repeated unless such a biopsy is considered unacceptable risk to the individual. Individuals without adequate tissue are eligible at the discretion of the PI.

- Must have disease that is measurable or evaluable on either computed tomography (CT) scans or FDG-positron emission tomography (FDG-PET) scans

NOTE: Since individuals with FL may have lesions that wax and wane on imaging, the requirement for disease being measurable or evaluable can come from imaging taken at any time at or after diagnosis, the most recent imaging prior to enrollment does not need to show measurable or evaluable disease.

- Age greater than or equal to 18 years

NOTE: Individuals with the pediatric-type follicular lymphoma are usually \<18 years of age, and often have a very different clinical course than individuals with the adult-type of FL. Due to this difference in biology, children are excluded from this study.

- performance status \<2 ( >60%)

Exclusion criteria

EXCLUSION CRITERIA:

  • Previous history of diffuse large B-cell lymphoma or histologic transformation
  • Any prior systemic treatment for lymphoma including cytotoxic chemotherapy, biologic therapy, and monoclonal antibody therapy (radiotherapy permitted); individuals who have received chemotherapy, biologic therapy, hormonal therapy, or monoclonal antibody for other are potentially eligible provided that all of the following are true: a) that malignancy was not lymphoma, b) systemic therapy ended at least 3 years prior to the diagnosis of FL, and c) there is no evidence of active malignancy other than FL

NOTE: Initiation of systemic therapy is allowed while on this trial; concurrent participation in first-line treatment clinical trials will be permitted.

  • Individuals who are -positive
  • Any second malignancy that requires active systemic therapy
  • Any other (non-lymphoma) life-threatening disease
  • Individuals unable to provide (surrogates will not be used)
  • Pregnant women are excluded from enrollment onto this study because the invasive procedures and/or sedation needed to perform them may cause unnecessary harm to the unborn fetus. In the event a woman becomes pregnant while on study, she will not be removed from the study; however, no follow-up invasive clinical or research procedures will be done that include unacceptable to risk to the participant and/or to the unborn fetus.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)

Groups and cohorts

  • 1

    Participants with grades 1-2 or 3a follicular lymphoma (FL)

06

What researchers measure

Primary outcomes

  1. Characteristics of treatment received (e.g., type, response, etc.) and molecular biology (e.g., pathology, histologic transformation) will be described

    The types and frequency of each treatment will be reported.

    Time frame: ongoing

  2. Time to initiation of first-line systemic treatment (TTT1), defined as the number of days from study enrollment until the date of initiation of first-line systemic treatment

    Number of days from study enrollment until the date of initiation of first-line systemic treatment will be reported.

    Time frame: 2 years

Secondary outcomes

  1. Progression-free survival

    The number of days from initial diagnosis until date of first objective progression or death from any cause

    Time frame: 2 years

  2. Progression-free survival after first-line systemic treatment, defined as the number of days from diagnosis to objective disease progression after first-line systemic treatment

    The number of days from diagnosis to objective disease progression after first-line systemic treatment or death from any cause

    Time frame: 5 years

  3. Progression-free survival from first active lymphoma treatment

    The number of days from initiation of first-line systemic treatment to objective disease progression or death from any cause

    Time frame: 5 years

  4. Time to initiation of second-line systemic treatment

    The number of days from study enrollment until the date of initiation of second-line systemic treatment

    Time frame: 5 years

  5. Overall survival (OS)

    The number of days from initial diagnosis until death from any cause

    Time frame: 10 years

07

Study locations

1 of 1 sites recruiting
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
    Recruiting
    • For more information at the NIH Clinical Center contact National Cancer Institute Referral Office · Contact888-624-1937
08

References and documents

Individual participant data

Plan to share: Yes — All IPD recorded in the medical record will be shared with intramural investigators upon request. @@@@@@All large scale genomic sequencing data will be shared with subscribers to dbGaP.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Clinical data available during the study and indefinitely.@@@@@@Genomic data are available once genomic data are uploaded per protocol GDS plan for as long as database is active.

Access criteria: Genomic data are available once genomic data are uploaded per protocol GDS plan for as long as database is active.@@@@@@Genomic data are made available via dbGaP through requests to the data custodians.

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2017 (actual). Primary completion is estimated for Jan 2029, 137 months after the start.

Of 55 non-industry observational studies under Lymphoma, Follicular, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 165. This study's planned 137 months is above that.

Counting every sponsor, half of 81 studies reached it within 49 months; a quarter within 34 and three quarters within 120.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2017
First posted
Jun 19, 2017
StartActual
Jul 27, 2017
Primary completionEst.
Jan 1, 2029
CompletionEst.
Jan 1, 2029
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
4 inclusion criteria edited, 1 removed; 4 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedHistologically or cytologically confirmed follicular lymphoma (FL), grades 1-2, or 3a confirmed by the Laboratory of Pathology, NCI; patientsindividuals who meet criteria for immediate initiation of systemic therapy are eligible
  • EditedNOTE: If biopsy was >12 months prior to enrollment OR adequate tissue is not available, tissue biopsy may be optionally repeated unless such a biopsy is considered unacceptable risk to the patientindividual. PatientsIndividuals without adequate tissue are eligible at the discretion of the PI.
  • EditedNOTE: Since patientsindividuals with FL may have lesions that wax and wane on imaging, the requirement for disease being measurable or evaluable can come from imaging taken at any time at or after diagnosis, the most recent imaging prior to enrollment does not need to show measurable or evaluable disease.
  • Removedto show measurable or evaluable disease.
  • EditedNOTE: PatientsIndividuals with the pediatric-type follicular lymphoma are usually <18 years of age, and often have a very different clinical course than patientsindividuals with the adult-type of FL. Due to this difference in biology, children are excluded from this study.
Exclusion criteria
  • EditedAny prior systemic treatment for lymphoma including cytotoxic chemotherapy, biologic therapy, and monoclonal antibody therapy (radiotherapy permitted); patientsindividuals who have received chemotherapy, biologic therapy, hormonal therapy, or monoclonal antibody for other malignancies are potentially eligible provided that all of the following are true: a) that malignancy was not lymphoma, b) systemic therapy ended at least 3 years prior to the diagnosis of FL, and c) there is no evidence of active malignancy other than FL
  • EditedPatientsIndividuals who are HIV-positive
  • EditedPatientsIndividuals unable to provide informed consent (surrogates will not be used)
  • EditedPregnant women are excluded from enrollment onto this study because the invasive procedures and/or sedation needed to perform them may cause unnecessary harm to the unborn fetus. In the event a woman becomes pregnant while on study, she will not be removed from the study; however, no follow-up invasive clinical or research procedures will be done that include unacceptable to risk to the patientparticipant and/or to the unborn fetus.
Nov 4, 2026
Show all 4 updates
  1. Nov 17, 2026
    Minor edits only
    + 1 other change: verification date
  2. Nov 9, 2026
    Minor edits only
    + 1 other change: verification date
  3. Nov 4, 2026
    Eligibility 4 inclusion criteria edited, 1 removed; 4 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedHistologically or cytologically confirmed follicular lymphoma (FL), grades 1-2, or 3a confirmed by the Laboratory of Pathology, NCI; patientsindividuals who meet criteria for immediate initiation of systemic therapy are eligible
    • EditedNOTE: If biopsy was >12 months prior to enrollment OR adequate tissue is not available, tissue biopsy may be optionally repeated unless such a biopsy is considered unacceptable risk to the patientindividual. PatientsIndividuals without adequate tissue are eligible at the discretion of the PI.
    • EditedNOTE: Since patientsindividuals with FL may have lesions that wax and wane on imaging, the requirement for disease being measurable or evaluable can come from imaging taken at any time at or after diagnosis, the most recent imaging prior to enrollment does not need to show measurable or evaluable disease.
    • Removedto show measurable or evaluable disease.
    • EditedNOTE: PatientsIndividuals with the pediatric-type follicular lymphoma are usually <18 years of age, and often have a very different clinical course than patientsindividuals with the adult-type of FL. Due to this difference in biology, children are excluded from this study.
    Exclusion criteria
    • EditedAny prior systemic treatment for lymphoma including cytotoxic chemotherapy, biologic therapy, and monoclonal antibody therapy (radiotherapy permitted); patientsindividuals who have received chemotherapy, biologic therapy, hormonal therapy, or monoclonal antibody for other malignancies are potentially eligible provided that all of the following are true: a) that malignancy was not lymphoma, b) systemic therapy ended at least 3 years prior to the diagnosis of FL, and c) there is no evidence of active malignancy other than FL
    • EditedPatientsIndividuals who are HIV-positive
    • EditedPatientsIndividuals unable to provide informed consent (surrogates will not be used)
    • EditedPregnant women are excluded from enrollment onto this study because the invasive procedures and/or sedation needed to perform them may cause unnecessary harm to the unborn fetus. In the event a woman becomes pregnant while on study, she will not be removed from the study; however, no follow-up invasive clinical or research procedures will be done that include unacceptable to risk to the patientparticipant and/or to the unborn fetus.
    + 2 other changes: description and arm descriptions
  4. Oct 16, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03190928
Responsible party
Sponsor
First posted
Jun 19, 2017
Start date
Jul 27, 2017
Primary completion
Jan 1, 2029 (estimated)
Completion
Jan 1, 2029 (estimated)
Last update
Nov 17, 2026

Study contacts

NCI Medical Oncology Referral Office
Contact
ncimo_referrals@nih.gov
(240) 760-6050
Rahul Lakhotia, M.D.
Contact
rahul.lakhotia@nih.gov
(240) 858-7242
Rahul Lakhotia, M.D.
principal investigator · National Cancer Institute (NCI)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion